Enzolytics’ VIRO Subsidiary Advances in HIV/AIDS Treatment Trials
ALLEN, TX / ACCESSWIRE / Aug. 8, 2023 – Enzolytics, Inc., a biotech company, and its subsidiary, Virogentics, Inc. (VIRO), marked a significant step forward today. VIRO, a part of the Company, revealed that they’ve obtained a permit to send treatments for volunteer HIV/AIDS patients at HEAL Africa Hospitals in GOMA, PRC, and Panzi Hospital in Bukavu, DRC.
Enzolytics Inc Stock Price Today | OTC ENZC Live Ticker – Investing.com
African Trial’s Impact on Global Health
The outcomes from this pilot clinical trial in Africa will greatly shape the upcoming European Medicine Authority (EMA) clinical trials, set to launch in late 2023 or early 2024. This trial is crucial in understanding how these treatments can benefit patients.
Sagaliam’s Extended Partnership
Sagaliam Acquisition Corp. (“NASDAQ:SAGA”) shared that they’re prolonging the time to finalize a business agreement with VIRO. The companies are making noteworthy progress in their collaboration.
Supporting a Shared Vision
Barry Kostiner, Sagaliam’s CEO, commended VIRO’s advancement in clinical and regulatory milestones. He mentioned their commitment to aiding people globally, underscoring the importance of their joint platform.
Progress Towards Treatment and Funding
VIRO’s Chief Scientific Officer, Harry Zhabilov, shared his optimism. He stated that their goal of providing immunotherapy to patients is drawing closer each day. The move to NASDAQ is anticipated to unlock funding opportunities.
Conclusion: Paving the Way for Healthier Tomorrows
Enzolytics and its VIRO subsidiary are actively working towards advancing healthcare solutions. The recent developments demonstrate a collective effort in improving treatment options for HIV/AIDS patients worldwide. As progress continues, hope grows for a brighter and healthier future.
ENZC – Enzolytics, Inc. Enters $450 Million Agreement to Propel Breakthrough Medical Technologies
